William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sami Corwin has given his Buy rating due to a combination of factors including the promising clinical data from Crispr Therapeutics AG’s in vivo gene-editing programs. The company’s CTX310 program has demonstrated significant reductions in triglycerides and LDL cholesterol, with particularly strong results at higher dosage levels. This positions Crispr Therapeutics AG competitively in the market, alongside other notable players such as Arrowhead and Regeneron.
Furthermore, the anticipated data from the CTX320 program, despite being delayed, is expected to benefit from insights into the evolving lipoprotein(a) landscape, potentially enhancing its impact. The ongoing development of CTX340 for refractory hypertension also adds to the company’s robust pipeline. These factors collectively support the Buy rating as they indicate a strong potential for future growth and competitive advantage in the gene-editing field.
In another report released today, Needham also maintained a Buy rating on the stock with a $81.00 price target.